Primary Biliary Cirrhosis Drugs Market Highlights The Competitive Scenario With Impact Of Drivers

Primary biliary cirrhosis, known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis includes itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages. Most people are diagnosed early, before the disease progresses. Delay in treatment of cirrhosis can cause liver failure and a liver transplant is necessary for survival. Diagnostic tests for primary biliary cirrhosis includes examination of elevated levels of IgM immunoglobulin levels, lipids, cholesterol and bilirubin, liver biopsy, ultrasonography, CT scanning or MRI. Increasing research and development activities and rising incidence of primary biliary cirrhosis is expected to be a major driver for growth of the primary biliary cirrhosis drugs market.

Get The Holistic SAMPLE With Research Methodology: https://www.coherentmarketinsights.com/insight/request-sample/1539

Primary Biliary Cirrhosis Drugs Market – Driver

Currently, only two FDA approved drugs, Ursodeoxycholic acid and Ocaliva, are available in market to reduce cirrhosis progression. However, large number of drugs are in clinical trials and this is expected to propel growth of the primary biliary cirrhosis drug market in the near future. For instance, in 2017, NGM Biopharmaceuticals, Inc. completed phase II clinical trials for its candidate drug NGM 282, an engineered variant of human hormone FGF19, to eliminate bile acid toxicity in primary biliary cirrhosis patients. NGM282 has a unique opportunity to leverage the dual targets of FGF19 without the potential non-tumorigenic property.

Click To Continue Reading On Primary Biliary Cirrhosis Drugs Market

You may be interested

Researchers Develop Novel Method to Fight Sepsis
Healthcare
Healthcare

Researchers Develop Novel Method to Fight Sepsis

Mohit Joshi - October 15, 2018

Researchers developed a novel method to fight sepsis, according to a study published on September 11, 2018. This study was conducted by the researchers at the Washington…

Digital Health Market Expansion to be Persistent During 2026
Business
Business

Digital Health Market Expansion to be Persistent During 2026

Albert R - October 12, 2018

"The Digital Health Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Digital Health Market research…

Medical Grade Hydrogel Market Poised to Take Off by 2026
Business
Business

Medical Grade Hydrogel Market Poised to Take Off by 2026

Albert R - October 12, 2018

"The Medical Grade Hydrogel Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Medical Grade Hydrogel…

Most from this category